These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22272928)

  • 1. Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study.
    Gajria K; Kosinski M; Schein J; Kavanagh S; Dubois D
    Patient; 2008 Jul; 1(3):223-38. PubMed ID: 22272928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
    Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
    Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
    Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
    Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
    Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
    Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
    Rauck R; Rapoport R; Thipphawong J
    Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
    Wallace M; Skowronski R; Khanna S; Tudor IC; Thipphawong J
    Curr Med Res Opin; 2007 May; 23(5):981-9. PubMed ID: 17519065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
    Sabatowski R; Giesecke T
    MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral osmotic hydromorphone (OROS) in patients with chronic severe pain due to osteoarthritis under daily routine conditions].
    Müller-Schwefe GH; Blimke B; Hesselbarth S; Giesecke T
    MMW Fortschr Med; 2014 Apr; 156 Suppl 1():23-9. PubMed ID: 24930329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.
    Hale ME; Nalamachu SR; Khan A; Kutch M
    J Pain Res; 2013; 6():319-29. PubMed ID: 23658495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping MOS Sleep Scale scores to SF-6D utility index.
    Yang M; Dubois D; Kosinski M; Sun X; Gajria K
    Curr Med Res Opin; 2007 Sep; 23(9):2269-82. PubMed ID: 17697450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.
    Hauber AB; Fleischmann J; Lothgren M; Wilson M; Lam A; Dubois D; Sabatowski R
    J Opioid Manag; 2011; 7(4):287-96. PubMed ID: 21957828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
    Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
    J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.
    Park CK; Kang HW; Oh IJ; Kim YC; Kim YK; Na KJ; Ahn SJ; Kim TO; Choi YJ; Song GA; Lee MK
    J Korean Med Sci; 2016 Dec; 31(12):1914-1921. PubMed ID: 27822929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
    Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
    J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.
    Lee KH; Kim MK; Hyun MS; Kim JY; Park KU; Song HS; Lee SA; Lee WS; Bae SH; Ryoo HM; Cho YY
    J Opioid Manag; 2012; 8(4):243-52. PubMed ID: 22941852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
    Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
    J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS) hydromorphone in opioid-naive cancer patients: Results of the Korean South West Oncology Group study.
    Song EK; Shim H; Han HS; Sun D; Lee SI; Kang MH; Lee K; Cho D; Cho IS; Park SY; Kim S; Yim CY
    Pain Res Manag; 2015; 20(6):293-9. PubMed ID: 26474382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.